MBD2 and cancer: KDM5 Inhibitors: The association of enzymes that could remove methyl groups from the active mark H3K4me3 and their increased expression in cancer has led to the development of selective inhibitors of KDM5 demethylases, which have been applied pre-clinically to evaluate their possible use in cancer therapy.